Role of Angiotensin II in Insulin-induced Microvascular Activity

Insulin Sensitivity Clinical Trial

Official title:

Role of Angiotensin II in Insulin-induced Microvascular Activity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01024543
• Other study ID #: MEC 06-2-074
• Status: Completed
• Phase: N/A
• First received: November 30, 2009
• Last updated: December 1, 2009
• Start date: October 2006
• Est. completion date: November 2009

Study information

• Verified date: December 2009
• Source: Maastricht University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
• Study type: Interventional

Clinical Trial Summary

In this study we hypothesize infusion of Angiotensin II improves the insulin-induced microvascular dilatation and therefore insulin-mediated glucose uptake. Objectives: Does infusion of Angiotensin II increase insulin-mediated glucose uptake via enhanced insulin-mediated microvascular function in healthy subjects?

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: November 2009
• Est. primary completion date: November 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1.18-60 years 2.Caucasian 3.Blood pressure <140/90 mmHg.

Exclusion Criteria:

1. Obesity (BMI>27kg/m2)

2. Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, heart failure)

3. Impaired glucose tolerance or diabetes mellitus according to the criteria of the ADA

4. Smoking

5. Alcohol use >4U/day

6. Use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids, NNSAIDs)

7. Pregnancy

8. Wearing contact lenses

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Insulin Sensitivity
• Microcirculation

Intervention

Drug:
• Angiotensin II
Angiotensin II
• Phenylephrine
Phenylephrine
• Placebo

Locations

Country	Name	City	State
Netherlands	Maastricht University Medical Centre	Maastricht, P.o. Box 5800, Netherlands

Sponsors (1)

Lead Sponsor	Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	functional recruitment of capillaries in the skin		January 2009	No
Secondary	perfused capillary density in the nailfold		January 2009	No
Secondary	Endothelium- (in)dependent vasodilatation of finger skin microcirculation		January 2006	No
Secondary	Insulin sensitivity		January 2009	No